NEWS OF THE WEEK
PLANT BIOCHEMISTRY: Researchers
identify enzymes that convert codeine to morphine in poppy plants
T
CH3O
SHU T T ERSTO CK
MAXIMIZING CODEINE
O H HO
CH3
CODM
HO
HE POPPY PLANT’S RECIPE for building mor-
phine generates other pharmaceutically useful painkillers such as codeine and thebaine along the way, but some of the important biosynthetic enzymes involved in the plant’s opioid production have long eluded researchers. Now, plant biochemists Jillian Hagel and Peter Facchini of the University of Calgary, in Alberta, are reporting genes for two previously unknown enzymes involved in morphine biosynthesis, including an enzyme called CODM that performs the final O-demethylation step that converts codeine into morphine (Nat. Chem. Biol., DOI: 10.1038/nchembio.317). The discovery of these genes could lead to new pharmaceutical codeine production methods, such as ones using microbial fermentation. Production of codeine currently relies on extraction of opioids from poppy plants (Papaver somniferum), followed by chemical modification of the noncodeine opioids. This work “is very important scientifically,” comments Philip Larkin, a plant biochemist at the Commonwealth Scientific & Industrial Research Organisation, Australia’s national science agency. “These genes have long been sought.” The enzyme responsible for converting codeine to morphine in poppy plants was thought to be a cytochrome P450 enzyme, but the culprit for the O-demethylation step turns out to be a dioxygenase— CODM—instead, Facchini says. When Hagel and Facchini, using a virus, reduced poppy expression of the CODM gene, they increased
N
H
CODEINE CREATOR The poppy plant
(above) makes codeine (scheme, top) on the way to morphine (scheme, bottom) using an enzyme called CODM.
O H HO
H
N CH3
codeine levels in plants from about 20% to about 65% of the total alkaloid content. At the same time, morphine levels decreased from about 70% to about 15% of the total, Facchini notes. The easiest way to commercialize the results would be to engineer out the CODM gene from opium plants so they are able to produce codeine but not morphine. However, strong opposition to genetically modifying plants, particularly in Tasmania and France, both suppliers of pharmaceutical opioids, stymies this avenue of commercialization, Facchini notes. Furthermore, the Tasmanian poppy industry is already raising codeine content in plants with some success “through mutations achieved independently from genetic engineering,” Larkin adds. Instead, Facchini and Hagel suggest getting bacteria or yeast to produce codeine by engineering biosynthetic genes into the microbes as perhaps a cheaper and less controversial alternative. Insulin is currently made this way, with little objection from the general public about the genetically engineered product. Furthermore, because opioids are controlled substances, microbial fermentation might be easier to regulate and monitor than production in plants.—SARAH EVERTS
CONGRESS Republican action to halt earmarks could hurt chemical trade In their effort to do something to halt politically risky earmarks, Republicans in the House of Representatives might have cost chemical companies millions of dollars in import tariffs. The March 11 Republican decision to impose a one-year moratorium on inserting special-interest projects into government spending bills includes the term “limited tariff benefit” in its list of banned requests. This action has raised concern because banning tariff benefits this year could delay passage of or kill
the miscellaneous tariff suspensions bill (H.R. 4380) now in Congress. This bill eliminates import duties on hundreds of items, most of them chemicals. Hundreds of companies request suspension of tariffs for specific products every year, and Democrats and Republicans insert these requests into a single bill so they can be passed all at once. The Administration vets the requests, each of which must cost the Treasury less than $500,000 per year. Chemical substances are involved in a large number of the re-
WWW.CEN-ONLINE.ORG
13
M ARC H 2 2 , 20 10
quests, and the tariff suspensions add up to many millions of dollars of savings to companies importing the items. William E. Allmond IV, vice president for government relations for the Society of Chemical Manufacturers & Affiliates, says SOCMA is disappointed by the Republican move. “These tariff suspensions really help companies,” Allmond says. “Any further delay in this process is putting many small companies in our industry at a financial disadvantage in trying to compete globally.”—DAVID HANSON
